Treatment | Entered early escape therapy | Week 12 response | Week 24 response | ||||||
ASAS20 | ASAS40 | ASAS 5/6 | BASDAI 50 | ASAS20 | ASAS40 | ASAS 5/6 | BASDAI 50 | ||
ADA* | No | √ | √ | √ | √ | √ | √ | — | √ |
ADA | No | √ | — | — | — | √ | — | √ | — |
ADA | No | √ | √ | √ | — | √ | √ | √ | √ |
ADA* | No | — | — | — | √ | √ | — | √ | √ |
ADA* | Yes | — | — | — | — | 0 | 0 | 0 | 0 |
ADA* | Yes | — | — | — | — | 0 | 0 | 0 | 0 |
PBO* | No | — | — | — | — | — | — | — | — |
PBO | Yes | — | — | — | — | + | 0 | 0 | 0 |
PBO* | Yes | — | — | — | — | + | + | + | + |
PBO* | Yes | — | — | — | — | 0 | 0 | 0 | 0 |
PBO* | Yes | — | — | — | — | + | + | + | + |
ADA, adalimumab; ASAS, ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PBO, placebo; √, Responder on blinded therapy; —, non-responder on blinded therapy; +, responder on early escape, open-label adalimumab; 0, non-responder on early escape, open-label adalimumab.
*Patients fulfilling Stage V radiographic criteria for TSA.